Article
SLCO1B1 variants as predictors of methotrexate-related toxicity in children with juvenile idiopathic arthritis.
Scandinavian journal of rheumatology - 1 May 2021
Roszkiewicz J, Michałek D, Ryk A, Swacha Z, Szmyd B, Smolewska E
Abstract excerpt
Objectives: Methotrexate (MTX) administered at the dose 10-15 mg/m2 is currently recommended as the first line therapy in most juvenile idiopathic arthritis (JIA) subtypes. Gastrointestinal side effects and hepatotoxicity are the most prevalent manifestations of MTX intolerance, frequently leading to discontinuation of otherwise effective treatment. Genetic variability within solute carrier organic anion...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
